Bromhexine

Identification

Name
Bromhexine
Accession Number
DB09019
Description

Bromhexine is an expectorant/mucolytic agent. Bromhexine is not available in the United States. It is marketed under the trade name Bisolvon(R) in Germany, England, Belgium, France, Italy, Netherlands, Norway, Sweden, Australia, and South Africa.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 376.13
Monoisotopic: 373.999323944
Chemical Formula
C14H20Br2N2
Synonyms
  • 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine
  • Bromexina
  • Bromhexina
  • Bromhexine
  • Bromhexinum
  • N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine
External IDs
  • NA 274

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Product Ingredients
IngredientUNIICASInChI Key
Bromhexine hydrochlorideYC2ZOM3Z8V611-75-6UCDKONUHZNTQPY-UHFFFAOYSA-N
International/Other Brands
Amiorel (Boehringer Ingelheim) / Bisolmed (Boehringer Ingelheim) / Bisolvon (Boehringer Ingelheim) / Bisolvon Chesty (Boehringer Ingelheim) / Fluibron

Categories

ATC Codes
R05CB02 — Bromhexine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylmethylamines
Alternative Parents
Benzylamines / 2-bromoanilines / Cyclohexylamines / Bromobenzenes / Aralkylamines / Aryl bromides / Trialkylamines / Primary amines / Organopnictogen compounds / Organobromides
show 1 more
Substituents
2-bromoaniline / Amine / Aniline or substituted anilines / Aralkylamine / Aromatic homomonocyclic compound / Aryl bromide / Aryl halide / Benzylamine / Bromobenzene / Cyclohexylamine
show 11 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organobromine compound, tertiary amino compound, substituted aniline (CHEBI:77032)

Chemical Identifiers

UNII
Q1J152VB1P
CAS number
3572-43-8
InChI Key
OJGDCBLYJGHCIH-UHFFFAOYSA-N
InChI
InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3
IUPAC Name
2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline
SMILES
CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1

References

Synthesis Reference

U.S. Patent 3,336,308.

General References
Not Available
KEGG Drug
D07542
PubChem Compound
2442
PubChem Substance
310264976
ChemSpider
2348
BindingDB
50239965
RxNav
1753
ChEBI
77032
ChEMBL
CHEMBL253376
ZINC
ZINC000000608220
Drugs.com
Drugs.com Drug Page
Wikipedia
Bromhexine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionIncreased Risk of SARS-CoV-2 Infection / Novel Coronavirus Infectious Disease (COVID-19)1
4RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
3RecruitingTreatmentAbnormal Mucus Secretions / Respiratory Tract Diseases1
3RecruitingTreatmentCOVID 19 / Novel Coronavirus Infectious Disease (COVID-19)1
0Enrolling by InvitationPreventionAntimalarials / Antirheumatic Agents / Enzyme Inhibitors / Hydroxychloroquine / Novel Coronavirus Infectious Disease (COVID-19)1
Not AvailableActive Not RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Novel Coronavirus Pneumonia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Granule8 MG
Injection, solution4 MG/2ML
SolutionOral2 MG/ML
Suppository16 MG
Suppository8 MG
Syrup4 MG/5ML
Syrup8 MG/5ML
Tablet8 MG
Tablet, soluble8 MG
SolutionOral8 MG/5ML
Tablet8 mg/1
SolutionOral80 mg
SyrupOral4 mg/5ml
Syrup200 ml
Tablet, sugar coatedOral8 mg/1
Tablet12 MG
SolutionOral12 MG/ML
SolutionOral8 MG/ML
SyrupOral0.16 g
SyrupOral0.08 g
PowderNot applicable1000 g/1000g
SolutionOral
Syrup100 ml
Powder
SyrupOral0.04 g
Tablet
Capsule, liquid filledOral8 mg
Solution
SyrupOral80 mg
SyrupOral40 mg
SolutionOral0.16 g
SyrupOral160 mg
SolutionOral0.08 g
SolutionOral0.04 g
TabletOral8 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)232-235U.S. Patent 3,336,308.
Predicted Properties
PropertyValueSource
Water Solubility0.00362 mg/mLALOGPS
logP4.08ALOGPS
logP4.42ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)19.89ChemAxon
pKa (Strongest Basic)9.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.26 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity85.56 m3·mol-1ChemAxon
Polarizability32.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0095000000-2c4f15e31beb22fd1178
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-4d3be1605bfa79609959
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-428c05c13a2a9e326945
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0390000000-b0ece5d5d6f8b78af198

Drug created on June 24, 2014 10:22 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates